Four-Gene Signature Targets Better Liver Cancer Trials
The identified markers aim to improve patient stratification for upcoming clinical trials of the drug Sapu003.
Updated on Oct. 26, 2026 in Biotech
Live Poll
Do you trust that AI-guided research will lead to faster development of effective medical treatments?
Oncotelic Therapeutics has identified a four-gene prognostic signature designed to improve patient stratification for its upcoming clinical trials of Sapu003. This research-stage development, published in Biomedicines, seeks to address previous stagnation in the clinical development of everolimus.
Why it matters
By refining patient selection through genetic markers, the company aims to move beyond earlier hurdles in everolimus therapy development. This approach could accelerate the path toward effective treatment for patients with hepatocellular carcinoma.
The researchers identified a four-gene signature comprising FKBP1A, EIF4E, RRAGC, and PPARGC1A. These markers were isolated using the Partitioned Literature Aggregation algorithm, which analyzes segmented literature groups before synthesizing transcriptomic and survival data.
The players
Oncotelic Therapeutics
An Agoura Hills-based biopharmaceutical company specializing in oncology drug development and AI-guided biological platforms.
Saran Saund
A researcher who presented the firm's findings on prognostic gene signatures at the 2026 Drug Discovery Strategic Summit.
The details
The team utilized the Partitioned Literature Aggregation algorithm, a process that examines discrete clusters of medical literature to extract signals before merging them for broader analysis. This AI-guided pipeline cross-referenced these findings with transcriptomic data—the full set of RNA transcripts in a cell—to identify patterns associated with hepatocellular carcinoma survival. The resulting four-gene profile serves as a biological roadmap for selecting trial candidates likely to respond to Sapu003, an intravenous form of the drug everolimus.
Timeline
October 22, 2026: Saran Saund presented the research at the 22nd Drug Discovery Strategic Summit.
October 23, 2026: The study was published in the journal Biomedicines.
October 26, 2026: Oncotelic Therapeutics officially announced the study results.
The Tech Race
This development marks a shift in how Oncotelic Therapeutics applies its PDAOAI discovery platform to bridge the gap between literature-based AI insights and clinical trial design. The company is currently scaling its discovery capacity toward a target of 100 billion biological vectors.
This research currently exists at the clinical trial design stage and does not impact immediate patient treatment protocols. Stakeholders and industry observers should watch for the initiation of clinical trials for Sapu003 to verify if the four-gene stratification improves patient outcomes.
The takeaway
The study provides a necessary framework for identifying high-potential trial participants for Sapu003. Future updates will center on the company's progress in clinical trials and the expansion of its PDAOAI discovery platform.
Further reading
Explore more developments in the field within the Biotech section.
More information
View the complete peer-reviewed study in Biomedicines for full methodology.
Live Poll
Do you trust that AI-guided research will lead to faster development of effective medical treatments?
